Related by context. All words. (Click for frequent words.) 72 OvaRex R 71 Azedra 70 BrachySil TM 70 Panzem R NCD 69 indibulin 69 PLK1 SNALP 69 IMA# 69 Neuradiab TM 69 ELACYT 68 depsipeptide 68 PXD# 68 CBLC# 67 YONDELIS 67 NP2 Enkephalin 67 Onconase 67 MGd 67 Tectin TM 67 EndoTAG TM -1 67 Dacogen injection 67 DOS# 67 GRNVAC1 67 Allovectin 7 ® 67 ONCONASE R 67 eniluracil 67 RIGScan CR 67 REOLYSIN ® 66 StemEx R 66 Trofex 66 trastuzumab DM1 T DM1 66 BrachySil 66 Urocidin TM 66 Xanafide 66 pain palliation 66 Virulizin ® 66 enzastaurin 66 deforolimus 66 CR# vcMMAE 66 MGCD# [001] 66 MAGE A3 ASCI 66 MAXY G# 66 elotuzumab 66 ularitide 66 OncoVEX GM CSF 66 Allovectin 7 66 Fibrin Pad 66 MEK inhibitors 66 OHR/AVR# 66 Onco TCS 66 TACI Ig 65 ATL# [001] 65 NEUMUNE 65 Proxinium TM 65 Cloretazine R VNP#M 65 alvespimycin 65 Curaxin 65 GED aPC 65 Androxal TM 65 synthetic retinoid 65 CCX# 65 INCB# [001] 65 preclinically 65 Exelixis compounds 65 Squalamine 65 GAMMAGARD 65 triphendiol 65 ganetespib 65 tesmilifene 65 OncoVEX 65 anticancer agent 65 EOquin TM 65 Aplidin 65 PRX# 65 liposomal formulation 65 JAK inhibitor 65 OvaRex ® MAb 65 Bezielle 65 recurrent GBM 65 phase IIb clinical 65 Phase Ib study 65 Symadex 65 PSMA ADC 65 custirsen 65 neratinib 65 cilengitide 65 pharmacokinetic characteristics 65 Zevalin consolidation 65 Temsirolimus 65 Phase #b/#a clinical 65 phase IIa clinical 65 Amplimexon 65 RSD# oral 64 Archexin 64 UVIDEM 64 vidofludimus 64 vosaroxin 64 oral prodrug 64 tecarfarin 64 CRLX# 64 Myocet 64 Aquinox 64 Cloretazine 64 PrevOnco ™ 64 Fodosine 64 therapeutic monoclonal antibody 64 MGN# 64 glufosfamide 64 Urocidin 64 ReN# 64 MEK inhibitor RDEA# 64 AeroLEF TM 64 Afatinib 64 Sym# 64 Proellex TM 64 Azedra TM 64 Phase IIb clinical trials 64 HDL Selective Delipidation 64 Anticalins R 64 Chemophase 64 radiation sensitizer 64 nonclinical studies 64 obatoclax 64 BLA submission 64 Zemplar Capsules 64 Phase #b/#a 64 elacytarabine 64 rBChE 64 EFAPROXYN 64 adecatumumab 64 bardoxolone 64 SUTENT ® 64 Phase Ib II 64 vascular disrupting agents 64 forodesine 64 PhG alpha 1 64 pharmacokinetic PK study 64 IL# PE#QQR 64 ALN VSP 64 Alocrest 64 LEUKINE 64 ospemifene 64 RhuDex ® 64 Fibrillex TM 64 atacicept 64 anti CD# antibodies 64 ENMD # 64 INTERCEPT platelets 64 Traficet EN 64 AQ4N 64 anti angiogenic agents 64 Tamibarotene 63 TKM ApoB 63 immunosuppressive regimens 63 Vectibix monotherapy 63 LNP formulations 63 PEG SN# 63 molecularly targeted 63 radiolabeled TM# 63 PI3K/Akt pathway inhibitor 63 Cloretazine ® 63 NB S# strontium malonate 63 GVAX Pancreas Vaccine 63 L BLP# 63 eTag assays 63 HER2 positive metastatic breast 63 ATL# [002] 63 antiangiogenic therapy 63 blinatumomab 63 IRX 2 63 concurrent chemoradiation 63 entinostat 63 GSK# [001] 63 Phase 1b clinical trials 63 PROCHYMAL 63 Solazed 63 therapeutic regimens 63 TRISENOX 63 nalbuphine ER 63 ONCONASE 63 tubulin inhibitor 63 Anticalins 63 lorvotuzumab mertansine 63 KNS # 63 AEG# 63 leading oral taxane 63 proteasome inhibitor 63 galiximab 63 velafermin belinostat 63 ASONEP 63 LungExpress Dx TM 63 samalizumab 63 tanespimycin 63 PREOS 63 histamine dihydrochloride 63 tramiprosate ALZHEMED TM 63 BEXXAR 63 myelofibrosis polycythemia vera 63 oral ridaforolimus 63 TBC# 63 PRECISE trial 63 Phase IIb III 63 romidepsin 63 NEUVENGE 63 SparVax TM 63 investigational therapies 63 SNT MC# 63 CA4P 63 IAP inhibitors 63 PROSTVAC TM 63 ApoB SNALP 63 Amrubicin 63 XmAb# 63 JAK2 inhibitors 63 EndoTAGTM 1 63 personalized immunotherapy 63 anticancer compound 63 NPC 1C 63 EP #R 63 anticancer therapies 63 MBP# [001] 63 imetelstat 63 Cloretazine R 63 Pyridorin 63 #D#C# 63 ancrod 63 paclitaxel Taxol ® 63 LE DT 63 TASQ 63 targeted radiotherapeutic 63 Lenocta 63 belinostat 63 preclinical efficacy 63 MyVax R 63 hypoxia activated prodrug 63 anticoagulant reversing agent 63 PEGPH# 63 otelixizumab 63 ixabepilone 63 HQK 63 Viprinex 63 immune modulating 63 Bicifadine 63 bevacizumab Avastin ® 63 Canvaxin TM 63 Tarvacin TM 63 Panzem R 63 AP# [003] 63 Allovectin 7 R 63 ALN TTR# 63 BioNumerik 63 CoFactor 63 Factor VIIa 63 sunitinib malate 63 GLP toxicology studies 63 OXi# 63 favorable pharmacokinetic profile 63 PDE4 inhibitor 63 HuLuc# 63 Adnectin 63 Asentar 62 Aurexis 62 Hepatocellular Carcinoma HCC 62 Cerashield 62 CYT# potent vascular disrupting 62 Curaxin CBLC# 62 pertuzumab 62 fosbretabulin 62 Virulizin 62 BRAF inhibitor 62 Carfilzomib 62 Pertuzumab 62 NovaBay Aganocide compounds 62 zanolimumab 62 oral deforolimus 62 ANYARA 62 rxRNA 62 HspE7 62 BLA filing 62 KIACTA ™ 62 Nanobody 62 liposomal doxorubicin 62 FOLOTYN ® 62 lomitapide 62 Telatinib 62 HGS# 62 eprotirome 62 OvaRex MAb 62 Atiprimod 62 afamelanotide 62 CINTREDEKIN BESUDOTOX 62 torezolid phosphate 62 PrevOnco 62 Shigamabs ® 62 Combidex 62 voreloxin 62 candidate TNFerade biologic 62 DCVax ® 62 tezampanel 62 cancer immunotherapies 62 SERMs 62 oral picoplatin 62 Phase IIIb clinical 62 ThermoDox R 62 XL# XL# 62 ARIKACE ™ 62 histone deacetylase inhibitor 62 rALLy trial 62 decitabine 62 BAY #-# 62 TAFA# 62 registrational 62 GRN#L 62 metaglidasen 62 GAP #B# 62 Dalbavancin 62 epigenetic therapies 62 CEQ# 62 monoclonal antibody therapeutics 62 cintredekin besudotox 62 teduglutide 62 dirucotide MBP# 62 HCD# [002] 62 CYT# 62 Aplidin R 62 OncoGel 62 MEND CABG II 62 Pimavanserin 62 Octreotide 62 isoform selective 62 MEK inhibitor 62 Intravenous CP 62 rindopepimut 62 Chrysalin 62 TheraSphere 62 Virulizin R 62 BiTE antibody 62 Bradmer 62 Cethrin 62 sorafenib tablets 62 lymphatic mapping 62 Combo Stent 62 generation purine nucleoside 62 Vascular Wrap TM 62 menadione 62 gefitinib Iressa 62 palifosfamide 62 Vaxfectin TM 62 Genasense ® 62 PhaseBio 62 novel oral anticoagulant 62 MYDICAR ® 62 DCVax R Brain 62 molecular biomarkers 62 Litx 62 Dacogen decitabine 62 cediranib 62 pralatrexate 62 cytotoxic agents 62 Anticalin ® 62 Bellicum Pharmaceuticals Inc. 62 Liprostin 62 AKT inhibitor 62 Gliadel Wafer 62 mertansine 62 Bayer HealthCare Onyx Pharmaceuticals 62 BNC# 62 epothilone 62 Anticalins ® 62 radiotherapeutic 62 Etubics 62 GFT# 62 Electronic Brachytherapy 62 farletuzumab 62 MNTX 62 mTOR inhibition 62 Velcade bortezomib 62 Zybrestat 62 Pemetrexed 62 SNALP technology 62 TOCOSOL Paclitaxel 62 XP# XP# 62 eculizumab 62 ISTODAX 62 LHRH antagonists 62 multitargeted 62 epigenetic therapeutics 62 HGS ETR2 61 bortezomib Velcade 61 Exelixis XL# 61 BEXXAR Therapeutic Regimen 61 FOLOTYN 61 carbohydrate polymers 61 GVAX immunotherapy 61 tosedostat 61 Onalta 61 metastatic HRPC 61 JAK inhibitors 61 EDEMA3 trial 61 TKM PLK1 61 Medidur FA 61 monoclonal antibody conjugated 61 EOquin 61 receptor tyrosine kinase inhibitor 61 pharmacokinetics pharmacodynamics 61 tesetaxel 61 Troxatyl 61 TEMODAL 61 Saforis 61 CD# antibody [001] 61 dosage regimens 61 anticancer therapy 61 Rescula 61 investigational monoclonal antibody 61 ZACTIMA 61 pomalidomide 61 immunotherapeutic vaccine 61 p# biomarker 61 potency selectivity 61 MDV# 61 IMC #B 61 CINQUIL 61 DXL# 61 EndoTAG TM 61 Phase Ib 61 JAK2 inhibitor 61 omecamtiv mecarbil 61 TG# [003] 61 PREOS R 61 encapsulates siRNAs 61 Darinaparsin 61 PET tracers 61 immune modulatory 61 talactoferrin 61 trastuzumab emtansine T DM1 61 INTEGRILIN 61 Vidofludimus 61 Civacir 61 Erimos 61 Degarelix 61 tranilast 61 haematological cancers 61 pharmacodynamic markers 61 cystinosis patients 61 drug eluting stent DES 61 XP #L 61 vernakalant hydrochloride 61 Phase IIB 61 SEPET TM 61 Tavocept 61 TLR9 agonists 61 sipuleucel T 61 BGC# 61 tyrosine kinase inhibitor 61 Hedgehog antagonist 61 drug GAP #B# 61 Tarvacin 61 Phase Ia 61 rPA anthrax vaccine 61 Exherin TM 61 ALN PCS 61 Plicera 61 DCVax R 61 torsemide ER 61 Excellarate 61 pharmacodynamic PD 61 dose escalation Phase 61 Oncaspar 61 microplasmin Phase III 61 C1 INH 61 Marqibo TM 61 Sulonex TM 61 HCV protease inhibitors 61 photodynamic therapy PDT 61 Anavex #-# 61 incyclinide 61 Revimmune 61 AZX# 61 nonsmall cell lung cancer 61 unique alkylating agent 61 Panzem 61 renin inhibitors 61 DPX Survivac 61 docetaxel Taxotere ® 61 SNS# T 61 Kevetrin ™ 61 zileuton CR 61 anti angiogenic drugs 61 randomized Phase 2b 61 dirucotide 61 cannabinor 61 sorafenib Nexavar 61 Specifid 61 Neovasc Reducer 61 ADVEXIN 61 ADVEXIN clinical 61 TransMID 61 calcineurin inhibitors 61 HuMax CD4 61 NeuroSTAT ® 61 siRNA therapeutics 61 Soliris eculizumab 61 SinuNase TM 61 PHX# 61 kidney urologic 61 TELINTRA 61 rALLy clinical trial 61 delafloxacin 61 preclinical toxicology 61 Bioaccelerate compounds under 61 XL# [003] 61 pan HDAC inhibitor 61 multicenter Phase II 61 novel peptide 61 R sorafenib tablets 61 BRIM2 61 acetonide FA 61 European Sepsis Trial 61 MammoSite RTS 61 optimal dosing 61 ProLindac TM 61 Radilex 61 Cotara 61 MAP# 61 drug ISA# 61 CTAP# Capsules 61 Thalomid ® 61 metastatic RCC 61 riociguat 61 antiangiogenic agents 61 pharmacodynamic parameters 61 volociximab 61 Cloretazine VNP#M 61 SILENOR 61 Phase Ib clinical 61 oral gallium 61 AzaSite Plus 61 EGS# 61 PSN# [001] 61 Genasense R oblimersen 61 clevidipine 61 REG1 61 BLP# Liposome Vaccine 61 Mipomersen 61 relapsed MM 61 Apoptone 61 evaluating REVLIMID 61 Cutanea 61 #ME# 61 vismodegib 61 erlotinib Tarceva 61 PEGylated interferon 61 oral antiviral 61 docetaxel Taxotere R 61 PORxin TM 61 Protexia ® 61 OMAPRO 61 faropenem 61 Alzhemed TM 61 SUTENT 61 tiapamil 61 GRN# 61 JAK1 61 Valdoxan 61 Phase III randomized controlled 61 BCX# 60 Kahalalide F 60 velafermin 60 Provecta 60 thalidomide Thalomid 60 PLX cells 60 ThermoDox 60 Phase IIa trials 60 MYCAMINE 60 investigational humanized monoclonal antibody 60 BST CarGel R 60 Annamycin 60 adipiplon 60 THR beta agonist 60 LibiGel Phase III 60 Phase 2a clinical trials 60 gemcitabine Gemzar ® 60 BR.# 60 XL# XL# XL# XL# 60 MOZOBIL 60 thymalfasin 60 AZD# 60 Quinamed 60 THALOMID 60 Lucanix R 60 Hematide ™ 60 Evoltra ® 60 mTOR inhibitors 60 ALN TTR 60 cMET 60 Oracea TM 60 Advexin 60 PDX pralatrexate 60 CobaCyte 60 systemic immunosuppressive drugs 60 ulimorelin 60 VitiGam 60 NeuVax 60 Insegia 60 rhMBL 60 CURE AF 60 dacetuzumab 60 MAXY VII 60 Guanilib 60 CAMPATH 60 Romidepsin 60 pharmacokinetic equivalence 60 FavId 60 Tarceva TM 60 ONCASPAR 60 PEP# [003] 60 SYNTAX trial 60 ZYBRESTAT fosbretabulin 60 ELND# 60 anti angiogenic therapy 60 LHRH antagonist 60 Perifosine 60 radiation dosimetry 60 JAK3 60 telomerase therapeutic 60 busulfan 60 amrubicin 60 CaPre TM 60 immunomodulator 60 Zerenex 60 oxymorphone ER 60 UPLYSO 60 polymerase inhibitors 60 lapatinib Tykerb 60 orally administered inhibitor 60 Nanobodies 60 postapproval 60 Octreolin 60 HGS ETR1 60 RenaZorb TM 60 sapacitabine 60 TRIST study 60 ONTAK 60 Lixivaptan 60 R#/MEM # 60 GEM OS2 60 radezolid 60 humanized antibodies 60 STRIDE PD 60 Stedivaze 60 Zemiva TM 60 therapeutic monoclonal antibodies 60 Vicinium TM 60 IDO inhibitor 60 BiTE 60 VITAL Trial 60 AGGRASTAT ® 60 rituximab Rituxan 60 Angiolix 60 Personalized Immunotherapy 60 octreotide implant 60 YONDELIS R 60 rNAPc2 60 orBec 60 alkylating agent 60 sorafenib Nexavar ® 60 iSONEP 60 AMPK activators 60 SILENOR ™ 60 ridaforolimus 60 Clolar ® 60 SNALP 60 ON #.Na 60 NEBIDO 60 Trofex TM 60 histone deacetylase HDAC 60 ganaxolone 60 RAV# 60 humanized anti 60 TLK# 60 Surgical resection 60 ORE# 60 theranostic 60 PNH patients 60 BrachySil ™ 60 BXT # 60 allogeneic HSCT 60 OPAXIO 60 teriflunomide 60 axitinib 60 ADVEXIN therapy 60 PRT# 60 TELCYTA 60 Edwards SAPIEN valve 60 EmbraceAC 60 superficial bladder cancer 60 CB1 antagonists 60 hematologic malignancies 60 elesclomol 60 optimal dosing regimens 60 Biomerk Tumorgrafts 60 ThermoDox ® clinical 60 fibrotic disease 60 Elafin 60 CD3 monoclonal antibody 60 Onalta TM 60 LHRH agonists 60 Perforomist ™ Inhalation Solution 60 nanopharmaceutical 60 oncolytic vaccine 60 Restanza 60 Aflibercept 60 Vandetanib 60 regenerative medicine therapies 60 ViaCyte 60 CIMZIA ™ 60 trial evaluating PRX# 60 EHT AGN 60 Tyrima 60 peginesatide 60 PS# [001] 60 AFRS TM 60 CRMD# 60 fusion enhancers 60 recurrent glioblastoma multiforme 60 Azedra ™ 60 MEND CABG 60 palliative radiotherapy 60 clinical pharmacology studies 60 bazedoxifene 60 Surfaxin LS 60 AdhTAP 60 TNFerade TM 60 OMP #M# 60 Dextofisopam 60 Prestara 60 LEP ETU 60 Pralatrexate 60 EGFR TKIs 60 APOPTONE 60 SIR Spheres 60 Triapine R 60 Targretin capsules 60 tramiprosate Alzhemed TM 60 EGFR HER2 60 methylnaltrexone 60 liposome formulations 60 romiplostim 60 biologic therapeutics 60 myeloproliferative disorders 60 oncology therapeutics 60 Phase #/#a trial 60 HERmark 60 HERmark assay 60 KRN# 60 Viprinex TM 60 AA amyloidosis 60 MyVax ® 60 Actimmune ® 60 Tesetaxel 60 candidate deforolimus 60 SILENOR TM 60 TYZEKA 60 PDE# inhibitors 60 ostarine 60 Soliris TM eculizumab 60 tolevamer 60 EXPAREL 60 Scancell 60 GGF2 60 HuCAL antibodies 60 ALTROPANE 60 ZEVALIN ® 60 lenalidomide Revlimid R 60 vorinostat 60 PSN# [002] 60 novel anticancer 60 Plenaxis TM 60 Ostabolin C TM 60 LNPs 60 oral talactoferrin 60 RH1 60 RNAi therapeutic targeting 60 CDK inhibitors 60 mitogen activated ERK kinase 60 phase IIb III 60 vemurafenib 60 miRNA therapeutics 60 trodusquemine 60 PNT# 60 lexidronam injection 60 myeloproliferative diseases 60 Xcellerated T Cells 60 sargramostim 60 Aviptadil 59 ThGRF 59 G#DT 59 non nucleoside HCV 59 CD# CEA 59 delivers fluocinolone acetonide FA 59 prognostic variables 59 Relivar 59 Teysuno 59 thoracoscopic lobectomy 59 brivaracetam 59 Reolysin 59 trastuzumab DM1 59 thetreatment 59 VAPRISOL 59 pegloticase 59 recurrent metastatic ovarian cancer 59 eprodisate Fibrillex TM 59 Solazed TM 59 demonstrated antitumor activity 59 evaluating satraplatin 59 TAXUS VI 59 Synavive 59 tafamidis 59 TRISENOX ® 59 paclitaxel Taxol R 59 varespladib 59 AutoloGel tm System 59 Protexia R 59 compound AEOL # 59 CardioPET 59 pharmacodynamic properties 59 tramiprosate 59 brostallicin 59 R roscovitine 59 Daclizumab 59 dalbavancin 59 chemoprevention trials 59 Vaxfectin R 59 colorectal liver metastases 59 IV Busulfex 59 Bioral Amphotericin B. 59 RECOTHROM R 59 ofatumumab HuMax CD# 59 Trovax 59 ruxolitinib 59 chemotherapeutic agents 59 PEG PAL 59 MAXY alpha 59 EyeGate 59 MEPACT 59 MAb 59 PEG Interferon lambda 59 Prodarsan ® 59 pharmacokinetic PK profile 59 nimotuzumab 59 multicenter clinical trials 59 CIP ISOTRETINOIN 59 combretastatin A4 phosphate CA4P 59 viral kinetics 59 Alequel ™ 59 Tasimelteon 59 refractory prostate cancer 59 oral taxane 59 Celator 59 Orqis Medical 59 trabectedin 59 efficacy endpoint 59 Menerba 59 pharmacokinetic pharmacodynamic 59 BEMA TM Fentanyl 59 Nicole Onetto MD 59 pharmacogenetic testing 59 LentiVector technology 59 Nanobody R 59 Targretin 59 external beam radiotherapy 59 chemotherapeutic drug 59 Clavis Pharma 59 Orazol 59 CA9 SCAN 59 Glufosfamide 59 Omacetaxine 59 antisense oligonucleotides 59 paclitaxel poliglumex 59 TOCOSOL Camptothecin 59 Bortezomib 59 ProMune 59 Nanobody ® 59 erythropoietic 59 AutoloGel tm 59 angiogenesis inhibitor 59 SUCCEED trial 59 PREGNANT Study 59 Stimuvax R 59 novel VDA molecule 59 antiangiogenic agent 59 humanized antibody 59 BMS# 59 Modrenal 59 PNP inhibitor 59 punctal plug 59 Bendavia 59 Voreloxin 59 Alpharadin 59 tremelimumab 59 novel histone deacetylase 59 GW# [003] 59 ADAGIO study 59 antitumor effect 59 ponatinib 59 Junovan 59 pediatric acute lymphoblastic 59 hematological cancers 59 pharmacodynamic profiles 59 AZILECT ® 59 BAL# [002] 59 SinuNase 59 immatics 59 talabostat 59 bafetinib 59 herpetic keratitis 59 GERD migraine headaches 59 compound AEZS 59 molecular chaperone amplification 59 NEUGENE 59 huC# DM4 59 TLR agonists 59 Cx# [002] 59 HuMax EGFr 59 EchoCRT 59 confirmatory Phase III 59 oral dnaJP1 59 regorafenib 59 Opterone 59 Prostate AdenoCarcinoma Treatment 59 acyclovir Lauriad R 59 Lovaxin C 59 PIX# [002] 59 Vectibix panitumumab 59 Vitaxin 59 luteinizing hormone releasing 59 Altastaph 59 novel therapeutic antibodies 59 Cerashield ™ 59 PF # [001] 59 abiraterone acetate 59 Ceflatonin R 59 Oral NKTR 59 antiangiogenic 59 Anticalin R 59 monoclonal antibody therapies 59 non nucleoside 59 lintuzumab 59 Teriflunomide 59 ZK EPO 59 direct thrombin inhibitors 59 docetaxel chemotherapy 59 Aloxi injection 59 relapsed ovarian cancer 59 immune modulator 59 cangrelor 59 Aurora kinase inhibitor 59 Cellegesic 59 alvimopan 59 olaparib 59 HuCNS SC ® 59 Imprime PGG 59 PGL# 59 Revlimid lenalidomide 59 allogeneic cell 59 LUVENIQ 59 Removab 59 Homspera 59 HCV protease inhibitor 59 RhuDex TM 59 OnDose TM 59 Lymphoseek 59 Phase 1b trial 59 Tesmilifene 59 topical formulations 59 Nuvion 59 Clofarabine 59 PROVENGE 59 Ceflatonin 59 indiplon capsules 59 ATIR 59 Preclinical studies suggest 59 ELND-#/AZD-# 59 Gemzar ® 59 DACH platinum 59 ClearPath HDR 59 EGFR inhibitors 59 Trastuzumab 59 immunomodulation 59 flavopiridol 59 Phase III psoriasis 59 secondary efficacy endpoints 59 novel mTOR inhibitor 59 synthetic siRNA 59 pretargeting 59 Neulasta ® 59 APTIMA HPV assay 59 RNA antagonist 59 Valortim 59 SonoLysis 59 StemEx